CN1375293A - Mixed vermifuge injection containing iodo-ether salicylamine - Google Patents
Mixed vermifuge injection containing iodo-ether salicylamine Download PDFInfo
- Publication number
- CN1375293A CN1375293A CN 02100633 CN02100633A CN1375293A CN 1375293 A CN1375293 A CN 1375293A CN 02100633 CN02100633 CN 02100633 CN 02100633 A CN02100633 A CN 02100633A CN 1375293 A CN1375293 A CN 1375293A
- Authority
- CN
- China
- Prior art keywords
- iodo
- ether
- ivermectin
- antioxidant
- prescription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention is an animal parasite expelling injection compound containing salicylic amine of iodine and ether with at least one kind of other vermifuges to be added in the formula which contains 1-35% (W/V) salicylic amine of iodine and ether in content and other vermifuges content of 0.1-30% (W/V). The other vermifuges include macrolide kind of vermifuge (abamectin, ivermectin, moxidectin, doramectin and eprinomectin) and tetraimidazole kind of vermifuge (levamisole). The preparation compound composed of these vermifuges and salicylic amine of iodine and other has the advantages of enlarged insect spectrum and medicinal effect better than single formulation.
Description
The present invention relates to a kind of anthelmintic formulation for animals, it is a kind of compound recipe veterinary injection that contains iodo-ether salicylamine.
Iodo-ether salicylamine (rafoxanide) is a kind of Salicylanilide anthelmintic, the adult of cattle, Hepar Caprae seu ovis sheet trematodiasis and big instar larvae is all had killing action, and haemonchus contortus and each phase sheep nose fly larva of a tapeworm or the cercaria of a schistosome are all had positive effect.When iodo-ether salicylamine and Macrolide anthelmintic composition compound preparation, enlarged insecticidal spectrum, simultaneously control of nematode in cattle, sheep epizoa and the body is had significant synergies, and when preparation of the present invention is main medium with lipophilic surfactant, preparation has slow release (long-acting) effect, the preparation good absorbing is to the injection site nonirritant.
In the present invention's prescription, the content range of iodo-ether salicylamine is 1-35% (W/V), and the content range of other anthelmintic is 0.1-30% (W/V), and all the other are disperse medium and other auxiliary agent (as surfactant and antioxidant).
Described other anthelmintic comprises: Macrolide anthelmintic (avilamycin abamectin, ivermectin ivermectin, moxidectin moxidectin, road draw rhzomorph doramectin and Ai Purui rhzomorph eprinomectin) and tetramisole class anthelmintic (levamisole levamisole).
The compound preparation that contains iodo-ether salicylamine among the present invention, the disperse medium that can add in the prescription comprises: water, vegetable oil, organic liquid medium, preferred organic liquid medium comprises isopropyl alcohol, n-butyl alcohol, hexanol, 1, the 2-propylene glycol, glycerol, Polyethylene Glycol, formal glycerine, benzyl alcohol, pyrrolidones such as N-methyl-ketopyrrolidine, azone, benzyl benzoate, glycerol triacetate, oleic acid, ethyl oleate, cyclic carbonates, aliphatic or aromatic alcohols, by monohydric alcohol or the synthetic fatty acid ester of polyhydric alcohol, as: monoglyceride compounds (glycerin mono-fatty acid ester, the glycerol monopalmitate, the glycerol aluminum monostearate), the diglyceride compounds is (as Imwitor, it is the monoglyceride and the diglyceride of caprylic/capric), the triglyceride compounds is (as Miglyol810,812,818, it is sad, capric acid and linolenic triglyceride), the list of propylene glycol and difatty acid ester type compound (propylene glycol dilaurate, the propylene glycol hydroxy stearic acid ester, the propylene glycol isostearate, the propylene glycol laurate, the propylene glycol ricinoleate ester, propylene glycol stearate, the propylene glycol caprylate, Miglyol 840, it is a propylene glycol caprylic/capric diester), fatty acid esters of sorbitan compounds (sorbitan list Lauryl Ester, the sorbitan monopalmitate, dehydration Pyrusussuriensis sugar ester stearoyl three esters, dehydrated sorbitol mono-fatty acid ester, sorbitan trioleate), pentaerythritol fatty ester class and polyalkylene glycol ethers compounds (tetramethylolmethane dioleate, pentaerythritol fatty ester, pentaerythritol stearate, pentaerythritol monostearate, the tetramethylolmethane laurate, pentaerythritol polyethylene glycol ether), the polyol ester compounds, the polyoxyethylene compounds, polyoxyethylene aliphatic alcohol ether, polyethenoxy alkylphenols, these disperse medium can use separately in prescription, also but two or more forms cosolvent or the use of compound dispersion medium, also can form Emulsion or microemulsion or dense dissolvable agents with surfactant.Described vegetable oil comprises Semen Maydis oil, Oleum Arachidis hypogaeae semen, Oleum sesami, Oleum Gossypii semen, Oleum Brassicae campestris, soybean oil, Oleum Helianthi, Oleum Ricini, almond oil, peach kernel oil, Oleum Cocois, Oleum Camelliae, olive oil and hydrogenated products thereof etc.
Described surfactant comprises anionic surfactant, cationic surface active agent, nonionic surfactant, preferred nonionic surfactants, preferred especially polyoxyethylene sorbitan fatty acid ester (Tween series), sorbitan fatty acid ester (Span series), castor oil polyoxyethylene ether (EL series) and alkylphenol polyoxyethylene (OP series) surfactant, these surfactants can use separately, but also two or more unites use.
The preferred preparation of the present invention consists of: (a) iodo-ether salicylamine 5-30% (W/V) (b) Macrolide anthelmintic 0.1-3% (W/V) (c) antioxidant 0.01-1% (W/V) (d) disperse medium add to 100% (V/V) (e) in case of necessity, add surfactant 1-70% (V/V).
The present invention further preferred preparation consists of: (a) iodo-ether salicylamine 10-30% (W/V) (b) ivermectin or AVM 0.2-3% (W/V) (c) N-methyl-pyrrolidones 0-50% (V/V) (d) phenmethylol 0-20% (V/V) (e) Ergol 0-60% (V/V) (f) vegetable oil 0-50% (V/V) (g) antioxidant 0.01-1% (W/V) (h) OP-4 or OP-10 or the particularly preferred preparation of Tween-80 0-60% (V/V) the present invention consist of:
The prescription A:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 0.7% (W/V) (c) N-methyl-ketopyrrolidine 20% (V/V) (d) antioxidant 0.3% (W/V) (e) benzyl benzoate add to 100% (V/V).
The prescription B:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 1% (W/V) (c) antioxidant 0.3% (W/V) (d) benzyl benzoate 60% (V/V) (e) OP-4 add to 100% (V/V)
The prescription C:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 1% (W/V) (c) Ergol 20% (V/V) (d) N-methyl-pyrrolidones 20% (V/V) (e) soybean oil 15% (V/V) (f) antioxidant 0.3% (W/V) (g) OP-4 add to 100% (V/V)
Prescription D:(a) iodo-ether salicylamine 30% (W/V) (b) ivermectin 1.5% (W/V) (c) N-methyl-ketopyrrolidine 45% (V/V) (d) antioxidant 0.5% (W/V) (e) OP-4 or OP-10 or Tween-80 add to 100% (V/V).
Described antioxidant comprises butylated hydroxyanisole (BHA) (BHA), butylated hydroxytoluene (BHT), gallic acid butyl ester, propyl gallate, methyl parahydroxybenzoate and propyl p-hydroxybenzoate etc., they can use separately, but also two or more unites use.
Above preparation is used to kill distoma hepaticum, nematicide and epizoa in cattle, the sheep body, and subcutaneous or intramuscular injection is pressed iodo-ether salicylamine and calculated, every kg body weight consumption is 6-12mg, press ivermectin or avilamycin and calculate, every kg body weight consumption is 0.3-1.0mg, and suitable consumption is 0.25-0.5mg/kg b.w.
With example preparation of the present invention is described below, but example do not limit the scope of the invention, scope of the present invention and core content are determined according to claims.
Example 1, this example are that preparation contains iodo-ether salicylamine 10%, the compound injection of avilamycin 0.7%.
Get iodo-ether salicylamine 1.1kg, add Polyethylene Glycol-200 6L dissolving, add the dimethylacetamide solution 200ml that contains avilamycin 70g again, mixing adds benzyl benzoate afterwards to 10L volume, filtration sterilization.
Example 2, this example are that preparation contains iodo-ether salicylamine 8%, the compound injection of ivermectin 0.5%.
Get iodo-ether salicylamine 8kg, ivermectin 0.5kg, add the dissolving of N-methyl-ketopyrrolidine 20L after, add ethanol 10L, tween 80 14L, 3 liters of OP-4,1 liter of OP-21, mixing adds water to 100 liters.
Example 3, this example are that preparation contains iodo-ether salicylamine 30%, the compound injection of ivermectin 1.5%.
Get iodo-ether salicylamine 30kg, ivermectin 1.5kg, antioxidant 0.3kg, add 45LN-methyl pyrrolidone dissolving after, add OP-10 to 100L.
Example 4, this reality are the compound injections that preparation contains iodo-ether salicylamine 20%, avilamycin 1%.
Get iodo-ether salicylamine 20kg, ivermectin 1.1kg, antioxidant 0.3kg, add benzyl benzoate and each 20L of N-methyl-ketopyrrolidine, make it dissolving, add soybean oil 15L afterwards, mixing, OP-4 to 100L again, mixing treats that the solution clarification promptly gets this preparation.
Claims (9)
1, a kind of compound recipe veterinary injection or oral liquid that contains iodo-ether salicylamine (rafoxanide) adds a kind of other anthelmintic at least in the prescription.Iodo-ether salicylamine content is 1-35% (W/V) in the prescription, and other anthelmintic content is 0.1-30% (W/V), and all the other are disperse medium and other auxiliary agent (surfactant, antioxidant etc.).
2,, it is characterized in that described other anthelmintic comprises Macrolide anthelmintic (drawing rhzomorph doramectin and Ai Purui rhzomorph eprinomectin as avilamycin abamectin, ivermectin ivermectin, moxidectin moxidectin, road) and tetramisole class anthelmintic (as levamisole levamisole etc.) by described compound recipe veterinary injection or the oral liquid that contains iodo-ether salicylamine of claim 1.
3, by claim 1 and the 2 described compound preparations that contain iodo-ether salicylamine, the disperse medium that can add in it is characterized in that filling a prescription comprises: water, vegetable oil, organic liquid medium; Preferred organic liquid medium comprises isopropyl alcohol, n-butyl alcohol, hexanol, 1, the 2-propylene glycol, glycerol, Polyethylene Glycol, formal glycerine, benzyl alcohol, pyrrolidones such as N-methyl-ketopyrrolidine, azone, benzyl benzoate, glycerol triacetate, oleic acid, ethyl oleate, cyclic carbonates, aliphatic or aromatic alcohols, by monohydric alcohol or the synthetic fatty acid ester of polyhydric alcohol, the polyol ester compounds, the polyoxyethylene compounds, polyoxyethylene aliphatic alcohol ether, polyethenoxy alkylphenols, these disperse medium can use separately in prescription, also but two or more forms cosolvent or the use of compound dispersion medium, also can form Emulsion or microemulsion or dense dissolvable agents (dense dose of microemulsion) with surfactant.Described vegetable oil comprises: Semen Maydis oil, Oleum Arachidis hypogaeae semen, Oleum sesami, Oleum Gossypii semen, Oleum Brassicae campestris, soybean oil, Oleum Helianthi, Oleum Ricini, almond oil, peach kernel oil, Oleum Cocois, Oleum Camelliae, olive oil and hydrogenated products thereof etc.
4, by claim 1 and 3 described preparations, it is characterized in that described surfactant comprises anionic surfactant, cationic surface active agent, nonionic surfactant, preferred nonionic surfactants, preferred especially polyoxyethylene sorbitan fatty acid ester (Tween series), sorbitan fatty acid ester (Span series), castor oil polyoxyethylene ether (EL series) and alkylphenol polyoxyethylene (OP series) surfactant, these surfactants can use separately, but also two or more unites use.
5, by the described preparation of claim 1, it is characterized in that preferred preparation consists of: (a) iodo-ether salicylamine 5-30% (W/V) (b) Macrolide anthelmintic 0.1-3% (W/V) (c) antioxidant 0.01-1% (W/V) (d) disperse medium add to 100% (V/V) (e) in case of necessity, add surfactant 1-70% (V/V).
6, by preparation claimed in claim 5, it is characterized in that preferred preparation consists of: (a) (b) (c) (d) (e) (f) (g) (h) OP-4 or OP-10 or Tween-80 0-60% (V/V) of antioxidant 0.01-1% (W/V) of vegetable oil 0-50% (V/V) of Ergol 0-60% (V/V) of phenmethylol 0-20% (V/V) of N-methyl-pyrrolidones 0-50% (V/V) of ivermectin or AVM 0.2-3% (W/V) of iodo-ether salicylamine 10-30% (W/V)
7, by the described preparation of claim 6, it is characterized in that particularly preferred preparation consists of:
The prescription A:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 0.7% (W/V) (c) N-methyl-ketopyrrolidine 20% (V/V) (d) antioxidant 0.3% (W/V) (e) benzyl benzoate add to 100% (V/V).
The prescription B:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 1% (W/V) (c) antioxidant 0.3% (W/V) (d) benzyl benzoate 60% (V/V) (e) OP-4 add to 100% (V/V)
The prescription C:(a) iodo-ether salicylamine 20% (W/V) (b) ivermectin 1% (W/V) (c) Ergol 20% (V/V) (d) N-methyl-pyrrolidones 20% (V/V) (e) soybean oil 15% (V/V) (f) antioxidant 0.3% (W/V) (g) OP-4 add to 100% (V/V)
Prescription D:(a) iodo-ether salicylamine 30% (W/V) (b) ivermectin 1.5% (W/V) (c) N-methyl-ketopyrrolidine 45% (V/V) (d) antioxidant 0.5% (W/V) (e) OP-4 or OP-10 or Tween-80 add to 100% (V/V).
8, by claim 6 and 7 described preparations, it is characterized in that described antioxidant comprises butylated hydroxyanisole (BHA) (BHA), butylated hydroxytoluene (BHT), gallic acid butyl ester, propyl gallate, methyl parahydroxybenzoate and propyl p-hydroxybenzoate etc., they can use separately, but also two or more unites use.
9, by claim 6 and 7 described preparations, it is characterized in that described preparation is used to kill distoma hepaticum, nematicide and epizoa in cattle, the sheep body, subcutaneous or intramuscular injection, pressing iodo-ether salicylamine calculates, every kg body weight consumption is 6-12mg, press ivermectin or avilamycin and calculate, every kg body weight consumption is 0.3-1.0mg, and suitable consumption is 0.25-0.5mg/kg b.w.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02100633 CN1375293A (en) | 2001-03-16 | 2002-01-29 | Mixed vermifuge injection containing iodo-ether salicylamine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01109660.8 | 2001-03-16 | ||
| CN01109660 | 2001-03-16 | ||
| CN 02100633 CN1375293A (en) | 2001-03-16 | 2002-01-29 | Mixed vermifuge injection containing iodo-ether salicylamine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1375293A true CN1375293A (en) | 2002-10-23 |
Family
ID=25740333
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02100633 Pending CN1375293A (en) | 2001-03-16 | 2002-01-29 | Mixed vermifuge injection containing iodo-ether salicylamine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1375293A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004047803A1 (en) * | 2002-11-27 | 2004-06-10 | Eco Animal Health Ltd | An injection of animal remedy including closantel or closantel sodium |
| WO2005084688A1 (en) * | 2004-03-04 | 2005-09-15 | Yuwan Wang | An injection power containing vermifuge |
| CN1867341B (en) * | 2003-10-17 | 2010-06-16 | 英特威国际有限公司 | Compositions for controlling parasites comprising a combination of abamectin and milbemycin |
| US9198430B2 (en) | 2011-06-23 | 2015-12-01 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
| CN114642632A (en) * | 2022-02-25 | 2022-06-21 | 河北科技大学 | Moxidectin injection and preparation method thereof |
-
2002
- 2002-01-29 CN CN 02100633 patent/CN1375293A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004047803A1 (en) * | 2002-11-27 | 2004-06-10 | Eco Animal Health Ltd | An injection of animal remedy including closantel or closantel sodium |
| CN1867341B (en) * | 2003-10-17 | 2010-06-16 | 英特威国际有限公司 | Compositions for controlling parasites comprising a combination of abamectin and milbemycin |
| WO2005084688A1 (en) * | 2004-03-04 | 2005-09-15 | Yuwan Wang | An injection power containing vermifuge |
| US9198430B2 (en) | 2011-06-23 | 2015-12-01 | Bayer New Zealand Limited | Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation |
| CN114642632A (en) * | 2022-02-25 | 2022-06-21 | 河北科技大学 | Moxidectin injection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE19781981B3 (en) | New pesticide combination | |
| CN101909450B (en) | Solvent systems for pour-on formulations for combating parasites | |
| RU2602189C2 (en) | Topical localized isoxazoline formulation comprising glycofurol | |
| DE60001774T2 (en) | Stable microemulsions for the administration of fatty acids and their use | |
| US20050192319A1 (en) | Spot-on formulations for combating parasites | |
| EP0697814B1 (en) | Pour-on formulations containinng polymeric material, glycols and glycerides | |
| US8993546B2 (en) | Parasiticidal composition | |
| EP2104426B1 (en) | Agents for controlling parasites on animals | |
| KR20080073700A (en) | Benzimidazole non-aqueous compositions | |
| CN1375293A (en) | Mixed vermifuge injection containing iodo-ether salicylamine | |
| EP2983712B1 (en) | Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent | |
| WO2005089550A2 (en) | Parasiticidal agents | |
| JP7394059B2 (en) | Antiparasitic pour-on composition | |
| CN1375287A (en) | Veterinary mixed suspension injection containing chlorocyaniosaliamine or its sodium salt | |
| CN1383821A (en) | Veterinary injection containing albendazole sulfoxide or its salt | |
| CN1435176A (en) | Triclabendazole-contg. preparation based on surfactant | |
| CN1376466A (en) | Solution-type oral liquid or injection containing triclabendazole | |
| AU764482B2 (en) | Pour-on formulations containing polymeric material, glycols and glycerides | |
| AU2013204176A1 (en) | Stable veterinary combination formulations of macrocyclic lactones and imidazothiazoles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |